Hinge Health (NYSE:HNGE) CEO Sells $2,502,352.80 in Stock

Hinge Health Inc. (NYSE:HNGE) CEO Daniel Antonio Perez sold 45,456 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $55.05, for a total transaction of $2,502,352.80. Following the sale, the chief executive officer directly owned 35,470 shares in the company, valued at $1,952,623.50. This trade represents a 56.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Antonio Perez also recently made the following trade(s):

• On Wednesday, May 6th, Daniel Antonio Perez sold 104,544 shares of Hinge Health stock. The stock was sold at an average price of $55.09, for a total transaction of $5,759,328.96.
• On Thursday, February 12th, Daniel Antonio Perez sold 166,665 shares of Hinge Health stock. The stock was sold at an average price of $40.26, for a total transaction of $6,709,932.90.

Hinge Health Trading Down 0.2%

Hinge Health stock opened at $55.89 on Monday. The firm’s 50 day simple moving average is $42.81 and its 200 day simple moving average is $44.00. The firm has a market capitalization of $4.40 billion and a PE ratio of -4.53. Hinge Health Inc. has a 1-year low of $30.08 and a 1-year high of $62.18.

Hinge Health (NYSE:HNGE) last posted its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. The business had revenue of $182.31 million for the quarter. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 279.39%. The business’s revenue was up 47.2% on a year-over-year basis. During the same period last year, the company posted $1.30 EPS. Research analysts forecast that Hinge Health Inc. will post 0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

HNGE has been the topic of several research reports. Stifel Nicolaus raised their price objective on shares of Hinge Health from $59.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Canaccord Genuity Group raised their price objective on shares of Hinge Health from $53.00 to $63.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays raised their price objective on shares of Hinge Health from $52.00 to $62.00 and gave the company an “overweight” rating in a research report on Wednesday. Truist Financial set a $79.00 price objective on shares of Hinge Health in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of Hinge Health from a “hold” rating to a “buy” rating in a research report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Hinge Health presently has an average rating of “Moderate Buy” and a consensus target price of $67.40.

Hedge Funds Weigh In On Hinge Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Hinge Health by 22.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company’s stock valued at $60,753,000 after buying an additional 228,234 shares during the period. Tudor Investment Corp ET AL boosted its position in Hinge Health by 25.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company’s stock valued at $18,467,000 after buying an additional 77,464 shares during the period. First Eagle Investment Management LLC purchased a new stake in Hinge Health during the 3rd quarter valued at $4,074,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Hinge Health by 755.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock valued at $1,271,000 after buying an additional 24,155 shares during the period. Finally, Braidwell LP purchased a new stake in Hinge Health during the 3rd quarter valued at $44,686,000.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.